MedTrace Logo

Oxytocin and Affect Processing in Posttraumatic Stress Disorder

NCT02546570 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2020-04-08

Study results available
· View outcomes & findings →

Summary

The investigators will use multiple methods (including Oxytocin intranasal inhalation, neuroimaging, behavioral measures, peripheral hormone measurements) to examine how individuals' behavior, cognition, and brain function is impacted by the neuro-hormone Oxytocin. Specifically, the investigators plan to evaluate the influence of Oxytocin administration on affective processing in non-trauma exposed and trauma-exposed adults (both with and without posttraumatic stress disorder, PTSD).

Conditions

  • Posttraumatic Stress Disorder (PTSD)

Interventions

DRUG

Oxytocin

See arm/group descriptions for dosage amount and procedure.

DRUG

Placebo

See arm/group descriptions for dosage amount and procedure.

Sponsors & Collaborators

  • National Center for PTSD

    collaborator FED

  • Yale University

    lead OTHER

Principal Investigators

  • Linda Mayes, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02546570 on ClinicalTrials.gov